|
|
|
IP Transactions
Steve Parker has represented clients in life sciences transactions for over 20 years, with an emphasis on licensing and other partnering and product development collaborations, and mergers and acquisitions.
Mr. Parker represents a wide range of clients, which have included:
- Pharmaceutical companies, such as Asahi Kasei Pharma, AstraZeneca, GlaxoSmithKline, Intendis (a subsidiary of Bayer), Sanofi-aventis and Shionogi Pharma;
- Numerous biotech and biopharmaceutical companies, including ArQule, Corinthian Opthalmic, EntreMed, Gilead Sciences, MacroGenics, Orion BioStategies, Sequella and Sucampo Pharmaceuticals;
- Medical device companies, such as GE Healthcare, Pharma-Pen and Plethora Solutions; and
- Non-profits and universities, such as AABB, The Center for Health Outcomes Research, eLife Sciences Publications Ltd. (a collaboration of Wellcome Trust, Howard Hughes Medical Institute and Max Planck Society), The Lieber Institute for Brain Development and University of Pittsburgh Medical Center.
Mr. Parker has been ranked by Chambers USA in the Life Sciences category every year since the category was created, and has been ranked several times in Chambers Global (Life Sciences) and Intellectual Property (Virginia). He is also the winner of the Washington Business Journal's "Top Washington lawyer" award for Technology Transactions.
His practice regularly involves transactions throughout the U.S., Europe and Asia.
IP Transactions Representative Matters
- GE Healthcare, in connection with the restructuring of its license to a bladder cancer diagnostic with Photocure ASA, and a partnership with Ipsen Pharmaceuticals
- Asahi Kasei Pharma, in its acquisition of all of the shares of Artisan Pharma
- eLife Sciences Publications Ltd, a collaboration of Wellcome Trust, Howard Hughes Medical Institute and Max Planck Society, in connection with its formation and initial operations
- Sequella, in a license and development agreement relating to its tuberculosis product to Maxwell Biotech for development and sale in Russia.
- Intendis GmbH (an affiliate of Bayer), in a license from Kythera Biopharmaceuticals
- Sanofi-aventis, in licensing matters
- The Lieber Institute in its partnership with Johns Hopkins University
- AstraZeneca, in various matters, including preclinical collaboration agreements and licenses to clinical compounds
- University of Pittsburgh Medical Center, in a partnership on vaccine development and production with a medical device manufacturer
- American Association of Blood Banks, in licensing and other transactional matters
- ArQule, in licenses and related agreements with Hoffmann-La Roche, Pfizer, and other partners; in its acquisition of Cyclis Pharmaceuticals and other business combination transactions; and in clinical trial matters
- Asahi Kasei Pharma, in its acquisition of all of the shares of Artisan Pharma
- AstraZeneca, in various matters, including preclinical collaboration agreements and licenses to clinical compounds
- AtheroGenics, in its license to AstraZeneca (cited as the biggest biotech deal of 2005 by Bio World) and with (then) Fujisawa
- Avalon Pharmaceuticals, in clinical trial matters
- Center for Health Outcomes Research, in research collaborations with pharmaceutical and biotech companies, and other life sciences organizations
- Charlesson LLC, in acquisitions
- eLife Sciences Publications Ltd, a collaboration of Wellcome Trust, Howard Hughes Medical Institute and Max Planck Society, in connection with its formation and initial operations
- EntreMed, in acquisitions and licensing transactions
- Gabriel Sciences, in licensing and intellectual property (IP) transactional matters
- GE Healthcare, in licensing and other transactional matters, including in connection with the restructuring of its license to a bladder cancer diagnostic with Photocure ASA, and a partnership with Ipsen Pharmaceuticals
- Gene Logic, in collaborations with partners, including Eli Lilly
- Gilead Sciences, in various licensing and collaboration matters, including with Japan Tobacco, Chiron, Achillion Pharmaceuticals, Genelabs, The Scripps Research Institute, and 4AZA Biosciences, and in its US$525 million purchase of royalty rights from Emory University
- GlaxoSmithKline, in licensing matters
- The Halifax Group, in in-licensing and IP issues associated with an acquisition
- Inflazyme, in its acquisition of GlycoDesign
- Intendis GmbH (an affiliate of Bayer), in a license from Kythera Biopharmaceuticals
- The Lieber Institute in its partnership with Johns Hopkins University
- MacroGenics, in licensing and other collaborations, including with Genzyme and with Green Cross; in its acquisition of Raven Biotechnologies; and in clinical trial agreements
- NED, Inc., in connection with its foundational agreements relating to its diagnostic technology
- Noxilizer, in connection with the development and commercialization of its sterilization technology
- Pharma-Pen, in its sale to West Pharmaceuticals
- Plethora Solutions, in its acquisition of a medical device company from Endocare
- RegeneRx, in licensing and other collaboration matters
- Sanofi-aventis, in licensing matters
- Sciele Pharma, in licensing matters, including with Galephar Pharmaceutical Research and Novo Nordisk
- Sequella, including in connection with a license and development agreement relating to its tuberculosis product to Maxwell Biotech for development and sale in Russia and a collaboration with the University of Maryland
- Shionogi Pharma, in connection with acquisitions
- SiteOne Therapeutics, in licensing and other transactional matters
- Steba Biotech, in licensing and related matters
- Sucampo Pharmaceuticals, in a license to Abbott Laboratories
- Symphogen, in a cross-license with Cambridge Antibody Technology
- Touro College, in life sciences matters, including the establishment of a life sciences incubator
- University of Pittsburgh Medical Center, in a partnership on vaccine development and production with a medical device manufacturer
- VIRxSYS, in licensing and acquisition matters, including its acquisition of Intronn
- Wave Inc., in strategic planning and licensing matters
- The Wellcome Trust, in transactional matters
- Whatman PLC, in its acquisition of assets from Life Technologies
- Several universities in life sciences matters, and clients in negotiating with dozens of different universities around the world, in connection with research and other collaboration agreements
- Several nonprofits, including TIGR, The Wellcome Trust, the American Red Cross, the American Association of Blood Banks, The Essel Foundation, and The Scripps Research Institute
- Several large pharmaceutical companies and specialty pharmaceutical companies, including in licenses, marketing and distribution agreements, collaborations, strategic counseling and transactional counseling
Chambers USA: America's Leading Lawyers for Business 2013 for Intellectual Property: Northern Virginia and Life Sciences: Corporate/Commercial Nationwide
Chambers USA: America's Leading Lawyers for Business 2012 for Intellectual Property: Northern Virginia and Life Sciences: Corporate/Commercial Nationwide
PLC Which lawyer? 2012: Recommended for Life sciences: Commercial and Partnering
Chambers Global 2012 for Life Sciences: Corporate/Commercial: Global-wide
PLC Which lawyer? Yearbook 2012: Endorsed for Mergers & Acquisitions
Named to SmartCEO's "Legal Elite" list, December 2011: "Steve has negotiated so many deal transactions that he has an excellent sense of how to structure even the most complex of relationships to the benefit of both parties."
Chambers USA: America’s Leading Lawyers for Business 2011 for Life Sciences: Corporate/Commercial (National) and Intellectual Property (Northern Virginia) (“He has a good sense of how to create a win-win situation, and how to assess the other side of the table. He is just superb.”)
Chambers Global: The World’s Leading Lawyers for Business 2011 for Life Sciences: Corporate/Commercial (Globally) (“Steve Parker handles a range of both licensing and M&A work from the firm’s Northern Virginia office and has a ‘very practical, level-headed attitude’.”)
PLC Which lawyer? Yearbook 2011 - Endorsed for Life Sciences: Commercial and Partnering (USA)
Chambers USA: America's Leading Lawyers for Business 2010 for Life Sciences: Commercial (National) and Intellectual Property (Northern Virginia) ("Steve Parker is highly praised for his patent licensing, partnerships and joint venture work.")
Chambers Global: The World's Leading Lawyers for Business 2010 for Life Sciences: Commercial (Globally) ("Steve Parker focuses on corporate transactions featuring pharmaceutical companies" and is hailed as one of two "superstars".)
Practical Law Company's Which lawyer? Yearbook 2010: Endorsed for Corporate/M&A (Washington, DC)
PLC Which lawyer? Yearbook 2009-2010 - Highly recommended for Life Sciences: Commercial and Partnering: "Prominent DC-based practitioner who has enjoyed a particularly active year with extensive experience of corporate finance, partnering and IP licensing issues."
Washington Business Journal's "Top Washington Lawyers" 2009: Winner for Technology Transactions
Chambers Global: The World's Leading Lawyers for Business 2009 for Life Sciences ("widespread market praise for his broad life sciences skills, which encompass M&A, joint ventures, patent licensing and corporate governance")
Chambers USA: America's Leading Lawyers for Business 2009 for Life Sciences: Commercial (National) and Intellectual Property (Northern Virginia) ("Acts on a number of transactional and licensing matters, particularly on behalf of pharmaceutical companies. Sources appreciate his analytical approach.")
PLC Which lawyer? Yearbook 2009: Recommended for Corporate/M&A: "Expert assisting life sciences in managing M&A and all related corporate matters of regulation and distribution."
Chambers USA: America's Leading Lawyers for Business 2008 for Life Sciences (National) and Intellectual Property (Northern Virginia) ("Steve Parker 'has a heavyweight nationwide presence, fully deserves his stellar reputation and is a fantastic guy, to boot.' He is especially lauded for his transactional work, and has worked on complex licensing matters, corporate governance and M&A matters." "Sources compliment his licensing and corporate due diligence work, describing him as 'phenomenally nice to work with, he has a keen ability to understand things from his clients' perspective.'")
Practical Law Company's Which lawyer? Yearbook 2008: Highly recommended for Life Sciences: Commercial and Partnering
Chambers USA: America's Leading Lawyers for Business 2007 for Life Sciences (National) ("Steve Parker is the 'first port of call for all issues thanks to his astounding breadth of knowledge,' say clients. Specializing in transactions, including licensing, M&A, technology transfers and collaborations, he has 'never let down a client and can be relied on without a shadow of a doubt,' according to interviewees.")
Practical Law Company's Cross-Border Competition Law Handbook 2007 for Mergers & Acquisitions
Practical Law Company's Which lawyer? Yearbook 2007: Highly recommended for IT and E-commerce
Practical Law Company's Which lawyer? Yearbook 2007: Recommended for Corporate/M&A
PLC Which lawyer? 2012 - Recommended for Corporate/M&A